• Neoadjuvante chemoradiatie: surgery when needed (preSANO)

• Neoadjuvante chemoradiatie: targeted treatment (TRAP)• Neoadjuvante/definitieve chemoradiatie: surgery if

possible (TOR)• Definitieve chemoradiatie: dosisintensificatie (ART-DECO)• Dataregistratie (POCOP)

Blik op de toekomst: lopende en geplande DOCG studies

Dr. Hanneke W.M. van LaarhovenMedische OncologieAcademisch Medische Centrum

preSANOpre- Surgery As Needed for Oesophageal carcinoma

A single-arm feasibility trial

Primary endpoint•Correlation between the clinical response during CRE-I and CRE-II and the final pathological response in the resection specimen

Secondary endpoints•Serious complications during endoscopic and endosonographic tissue sampling •R0-resection rates for all included patients that undergo resection

TRAPChemoradiation, TRAstuzumab and Pertuzumab in resectable

HER2+ esophageal carcinomaA single arm feasibility study

Primary endpoint•Withdrawal rate from surgery

Secondary endpoints•pCR•Toxicity•Post-operative complications

TOR

Chemoradiotherapy followed by resection for patients with gevolgd a T4b oesofagus carcinoma

Primary endpoint•R0 resection (≥ 80% )

Secondary endpoints•Post-operative complications•Mortality•Quality of life

ART-DECO

A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with

Oesophageal cancer

Landelijk Platform Radiotherapie voor Gastro Enterologische tumoren

Primary endpoint•Local recurrence rate (≥ 15% difference)

Secondary endpoints•Grade 3-4 toxicity•Survival

POCOPProspective Observational Cohort Study of

Oesophageal-gastric cancer Patients

Acknowledgments• Joel Shapiro, Bas Wijnhoven, Jan van Lanschot (preSANO)• Maarten Anderegg, Mark van Berge Henegouwen (TOR)• Maarten Hulshof (ART-DECO)• Leonie Haverkamp, Jelle Ruurda (Oesofagus/maag parel)